Repotrectinib Post-Marketing Surveillance in Pediatric Patients With NTRK Fusion-Positive Tumors in Japan
← catalyst calendarNCT07755826 · readout in 2,810 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
20estimated
Sites
2
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-11-20 | actual | When the study began enrolling |
| Primary completion | 2034-04-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2034-04-30 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- NTRK Fusion-positive Solid Tumors
Intervention
- Drug: Repotrectinib
Primary outcomes
what the primary-completion date above is the date OFNumber of participants with 1 or more adverse events (AEs)
measured Up to week 104
Number of participants with 1 or more serious adverse events (SAEs)
measured Up to week 104
Number of participants with adverse events by system organ class (including central nervous system disorders, interstitial lung disease, and fractures)
measured Up to week 104
Number of participants with adverse events (AEs) leading to treatment modification (interruption, dose reduction, or discontinuation)
measured Up to week 104
Number of participants with each adverse event outcome category (resolved, resolving, not resolved, resolved with sequelae, death, unknown)
measured Up to week 104
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed